Falsified GLP-1 Medicines: Regulator Warnings
Overview of Falsified GLP-1 Products
Global demand for diabetes and weight-loss treatments has driven an increase in counterfeit and falsified products entering the supply chain ([Multifactor Quality and Safety Analysis)]. The World Health Organization (WHO) issued a medical product alert regarding falsified semaglutides, which belong to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (WHO Alert). These medications are prescribed to lower blood sugar levels in type 2 diabetes and reduce cardiovascular risks ([WHO Alert)]. Because they also suppress appetite, they are increasingly prescribed for weight loss globally ([WHO Alert)].
The WHO Global Surveillance and Monitoring System has tracked rising reports of falsified semaglutide products across multiple regions since 2022 ([WHO Alert)]. Genuine versions of these medicines are typically administered through subcutaneous self-administration or taken as oral tablets ([WHO Alert)]. Supply shortages and high demand have created opportunities for illicit online sellers to distribute unverified products ([Multifactor Quality and Safety Analysis)].
Affected Products and Batches
The WHO medical product alert specifically addressed three falsified batches of the Ozempic brand of semaglutide ([WHO Alert)]. These falsified batches were detected in the United Kingdom and Brazil in October 2023, followed by the United States in December 2023 ([WHO Alert)]. The genuine manufacturer, Novo Nordisk, confirmed that these identified goods were falsified and misrepresented their source ([WHO Alert on Ozempic))].
Research studies evaluating products sold by online vendors without a prescription found that test purchases often involved non-delivery scams or delivered vials that failed visual inspection criteria significantly ([Multifactor Quality and Safety Analysis)]. Laboratory analysis of these purchased samples revealed that active ingredient amounts deviated substantially from labeled quantities, and endotoxins were detected in the tested vials ([Multifactor Quality and Safety Analysis)]. Furthermore, measured purity levels were extremely low compared to manufacturer claims ([Multifactor Quality and Safety Analysis)].
Health Risks of Counterfeit Treatments
Falsified medical products pose severe health risks to consumers ([WHO Alert on Ozempic))]. When products lack the correct active components, patients face health complications resulting from unmanaged blood glucose levels or unmanaged weight ([WHO Alert)]. In some instances, falsified injection devices have been found to contain undeclared active ingredients such as insulin, which can lead to unpredictable and potentially life-threatening health events ([WHO Alert)].
Additional hazards include contamination with harmful substances, incorrect concentrations leading to improper strength, and sterility issues arising from unknown ingredients used in illicit manufacturing (WHO Alert on Ozempic)). These risks are heightened when products are acquired through informal or online channels without medical oversight (WHO Alert on Ozempic)). Regular public updates and surveillance help track these dangerous items across international markets ([Full List of WHO Alerts)].
Regulatory Responses and Guidance
Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, advised healthcare professionals, regulatory authorities, and the public to remain vigilant regarding these falsified batches ([WHO Alert)]. International health agencies call on stakeholders to stop using suspicious items and report them to relevant national authorities ([WHO Alert)].
National regulatory bodies are encouraged to increase monitoring of informal and online sales channels, contact marketing authorization holders to identify counterfeits, and notify the WHO immediately upon discovering falsified goods (WHO Alert on Ozempic)). Consumers can protect themselves by obtaining medicines exclusively through licensed physicians and authorized suppliers rather than unfamiliar online sources ([WHO Alert), (WHO Alert on Ozempic))]. Public awareness and stringent supply chain security remain top priorities for safeguarding patients against substandard medical products ([Multifactor Quality and Safety Analysis)].
FAQ
What is a falsified GLP-1 medicine?
A falsified GLP-1 medicine is a product that falsely misrepresents its identity, source, or manufacture, such as counterfeit versions of Ozempic identified by the WHO (WHO Alert on Ozempic)). These items may contain incorrect ingredients, harmful contaminants, or incorrect amounts of active compounds ([Multifactor Quality and Safety Analysis)].
Which regions reported falsified semaglutide batches?
The WHO noted that specific falsified batches of Ozempic were detected in Brazil, the United Kingdom, and the United States (WHO Alert). The WHO Global Surveillance and Monitoring System has observed rising reports across all geographical regions since 2022 ([WHO Alert)].
What health hazards are linked to counterfeit injections?
Counterfeit injections can cause unmanaged blood glucose levels or unexpected health complications if they lack proper ingredients or contain undeclared substances like insulin ([WHO Alert)]. Laboratory testing also detected endotoxins and significant purity deviations in illicit samples ([Multifactor Quality and Safety Analysis)].
What do regulators advise people to do regarding suspicious products?
The WHO advises individuals to stop using suspicious medicines, avoid buying from unverified online sources, and obtain products only through authorized suppliers and licensed prescriptions ([WHO Alert), (WHO Alert on Ozempic))]. Anyone who may have used an affected product is advised to seek immediate medical advice (WHO Alert on Ozempic)).
How do illegal online pharmacies distribute these products?
Research shows that illegal online pharmacies market semaglutide products without requiring a prescription ([Multifactor Quality and Safety Analysis)]. Investigations revealed that some online offers result in non-delivery e-commerce scams or deliver substandard vials with low purity levels ([Multifactor Quality and Safety Analysis)].
For more details on regulatory oversight, view our how we rate framework or explore seller ratings on our platform.
This article is for information only and is not medical advice. Retatrutide is an investigational compound and is not approved for general medical or consumer use in South Africa.